

Wasat Mansoor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3102835/publications.pdf>

Version: 2024-02-01

25
papers

3,380
citations

623734

14
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

4085
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. <i>Journal of Clinical Oncology</i> , 2022, 40, 382-391. | 1.6 | 13 |
| 2 | Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. <i>Gastric Cancer</i> , 2021, 24, 970-977. | 5.3 | 5 |
| 3 | Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from <sc>REGARD</sc>, <sc>RAINBOW</sc>, and <sc>RAINFALL</sc> Phase <sc>III</sc> Studies. <i>Oncologist</i> , 2021, 26, e1538-e1547. | 3.7 | 19 |
| 4 | Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours. <i>Neuroendocrinology</i> , 2020, 110, 413-421. | 2.5 | 23 |
| 5 | Diagnostic and Management Pathways for Pulmonary Carcinoid Tumours in the United Kingdom: Results from the National Lung Neuroendocrine Tumour Pathway Project. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-9. | 1.5 | 2 |
| 6 | Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreaticobiliary cancers: A UK study. <i>Journal of Cancer Policy</i> , 2020, 25, 100236. | 1.4 | 3 |
| 7 | Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435. | 10.7 | 191 |
| 8 | The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1729-1741. | 1.7 | 9 |
| 9 | Prognostic significance of positive circumferential resection margin post neoadjuvant chemotherapy in patients with esophageal or gastro-esophageal junction adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 439-445. | 1.0 | 17 |
| 10 | Early recognition of anorexia through patient-generated assessment predicts survival in patients with oesophagogastric cancer. <i>PLoS ONE</i> , 2019, 14, e0224540. | 2.5 | 13 |
| 11 | Predictive factors of thromboembolic complications in patients with esophagogastric adenocarcinoma undergoing preoperative chemotherapy. <i>Acta Oncologica</i> , 2018, 57, 790-798. | 1.8 | 12 |
| 12 | Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1437-1448. | 10.7 | 345 |
| 13 | Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations. <i>Endocrine Pathology</i> , 2018, 29, 259-268. | 9.0 | 21 |
| 14 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133. | 13.7 | 984 |
| 15 | Genomic loss of heterozygosity and survival in the REAL3 trial. <i>Oncotarget</i> , 2018, 9, 36654-36665. | 1.8 | 13 |
| 16 | Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. <i>Medical Oncology</i> , 2017, 34, 116. | 2.5 | 6 |
| 17 | Prognostic Significance of CD44 and Orthopedia Homeobox Protein (OTP) Expression in Pulmonary Carcinoid Tumours. <i>Endocrine Pathology</i> , 2017, 28, 60-70. | 9.0 | 38 |
| 18 | Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1652-1664. | 10.7 | 108 |

| # | ARTICLE | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 19 | Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma. <i>Acta Oncologica</i> , 2017, 56, 1224-1232. | 1.8 | 1 |
| 20 | Gefitinib and <i>EGFR</i> Gene Copy Number Aberrations in Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2279-2287. | 1.6 | 100 |
| 21 | Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. <i>BMC Cancer</i> , 2016, 16, 779. | 2.6 | 3 |
| 22 | Diagnostic Utility of Orthopedia Homeobox (OTP) in Pulmonary Carcinoid Tumors. <i>American Journal of Surgical Pathology</i> , 2016, 40, 738-744. | 3.7 | 37 |
| 23 | Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. <i>Lancet Oncology</i> , The, 2014, 15, 894-904. | 10.7 | 270 |
| 24 | Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 78-86. | 10.7 | 516 |
| 25 | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 481-489. | 10.7 | 631 |